Recently, drugs directed against the FLT3 mutation (midostaurin) and the isocitrate dehydrogenase-2 (IDH2) mutation (enasidenib) and IDH1 (ivosidenib) became available to treat some forms of acute myeloid leukemia and systemic mastocytosis (midostaurin).